Can MRK's New Drugs & Pipeline Help Navigate the Looming Keytruda LOE?

Merck leans on a fast-growing pipeline and new product launches to aid long-term growth as Keytruda's 2028 LOE nears.

Zacks Investment Research • Dec 12, 2025

Merck Receives Positive EU CHMP Opinion for Expanded Use of WINREVAIR™ (sotatercept) in Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1 Pulmonary Hypertension)

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommended the approval of an expanded indication for WINREVAIR™ (sotatercept), in combination with other pulmonary arterial hypertension (PAH) therapies, for the treatment of PAH in adult patients with WHO Functional Class (FC) II, III, and IV based on the Phase 3 ZENITH study. The cur.

Business Wire • Dec 12, 2025

Here Are 2 Affordable Healthcare Stocks to Buy Heading Into 2026

One of these pharmaceutical leaders overcame a major obstacle and has a strong outlook. The other is actively pushing greater innovation to get around a rapidly approaching patent cliff.

The Motley Fool • Dec 12, 2025

Merck (MRK) Laps the Stock Market: Here's Why

Merck (MRK) closed at $99.01 in the latest trading session, marking a +1.42% move from the prior day.

Zacks Investment Research • Dec 11, 2025

Dividend Stocks for 2026: Where to Invest as the Market Cools

As we enter the final stretch of 2025, it's clear that this has been a strong year for equities. However, with valuations across the tech sector stretched and talk of an AI-fueled bubble growing louder, many investors are beginning to look for more stable, income-generating opportunities.

MarketBeat • Dec 10, 2025

2 Pharmaceutical Stocks to Buy at a Discount

Weight loss drugs are the big story in the pharmaceutical industry today, but other opportunities exist, too. Bristol Myers Squibb isn't focused on weight loss, has an attractive yield, and continues to cover its dividend.

The Motley Fool • Dec 10, 2025

FDA approves Merck drug for decimated U.S. cattle herds to stop screwworm

The U.S. Food and Drug Administration granted conditional approval for a Merck Animal Health pour-on treatment for the prevention and treatment of New World Screwworm, with farmers able to receive doses by December 20. U.S. cattle herds are at historic lows, pressuring beef prices, with the parasite from Mexico among multiple reasons for the decline in ranchers' livestock.

CNBC • Dec 9, 2025

Here's 1 Major Catalyst Behind Merck Stock's Recent 3.8% Bump

Merck spent a small fortune on the acquisition of Acceleron Pharma, and so far, it's paying off. Recent phase 2 data suggests the pharmaceutical giant could get even more bang for its buck.

The Motley Fool • Dec 9, 2025

Formycon and Zydus partner for exclusive licensing and supply agreement of FYB206, a biosimilar to Keytruda® (Pembrolizumab), in the U.S. and Canada

PLANEGG-MARTINSRIED, Germany and AHMEDABAD, India, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Formycon AG (FSE: FYB, “Formycon”) and Zydus Lifesciences Limited (including its subsidiaries and affiliates, “Zydus”), today jointly announced that they have entered into a strategic partnership for the exclusive licensing and supply of checkpoint inhibitor FYB206, a biosimilar of Keytruda®1 (Pembrolizumab), in the U.S. and Canada.

GlobeNewsWire • Dec 9, 2025

MRK Stock Trading Above 200- & 50-Day SMA for 2 Months: Time to Buy?

Merck holds bullish momentum as pipeline advances and major deals offset vaccine weakness and Keytruda risks.

Zacks Investment Research • Dec 9, 2025